US drug major Eli Lilly (NYSE: LLY) has announced full year revenues for 2016 guidance, which misses analyst estimates partly from the impact of foreign-exchange headwinds.
The company said it expects sales in 2016 in the range of $20.2 billion and $20.7 billion, below analyst estimates of $21.4 billion, partly hurt by the strong dollar. Earnings per share are forecast between $3.45 and $3.55, against analyst estimates of $3.65 per share.
Eli Lilly maintained its full-year 2015 earnings per share outlook at $3.40 to $3.45.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze